about
Post-Genomics and Vaccine Improvement for LeishmaniaEliminating the Neglected Tropical Diseases: Translational Science and New Technologies.A dual drug sensitive L. major induces protection without lesion in C57BL/6 miceAntimony resistant Leishmania donovani but not sensitive ones drives greater frequency of potent T-regulatory cells upon interaction with human PBMCs: role of IL-10 and TGF-β in early immune responsePreclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccineRecent advances in phlebotomine sand fly research related to leishmaniasis controlEpidemiology of visceral leishmaniasisA third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.Identification of etiologic agents of cutaneous Leishmaniasis in palpebral position followed by effective therapy.Insilico analysis of hypothetical proteins unveils putative metabolic pathways and essential genes in Leishmania donovani.Intranasal vaccination with extracellular serine proteases of Leishmania amazonensis confers protective immunity to BALB/c mice against infectionAn overview on Leishmania vaccines: A narrative review article.Prediction of CD8+ Epitopes in Leishmania braziliensis Proteins Using EPIBOT: In Silico Search and In Vivo Validation.Double-Blind Randomized Efficacy Field Trial of Alum Precipitated Autoclaved Leishmania major (Alum-ALM) Vaccine Mixed With BCG Plus Imiquimod Vs. Placebo Control Group.Immunologic progression of canine leishmaniosis following vertical transmission in United States dogs.The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice.Rodenticide Comparative Effect of Klerat® and Zinc Phosphide for Controlling Zoonotic Cutaneous Leishmaniasis in Central Iran.Therapeutic vaccines for leishmaniasis.Leishmania vaccine development: exploiting the host-vector-parasite interface.Total Leishmania antigens with Poly(I:C) induce Th1 protective response.Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach.Genome-Wide Prediction of Vaccine Candidates for Leishmania major: An Integrated Approach.Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice.Immune response to recombinant Leishmania infantum lipophosphoglycan 3 plus CpG oligodeoxynucleotides in BALB/c mice.Antigenic profile of heat-killed versus thimerosal-treated Leishmania major using sodium dodecyl sulfate-polyacrylamide gel electrophoresisSegregated growth kinetics of Escherichia coli DH5α-NH36 in exponential-fed perfusion culture for pDNA vaccine production.Buparvaquone Nanostructured Lipid Carrier: Development of an Affordable Delivery System for the Treatment of Leishmaniases.TLR2 and TLR4 in cutaneous leishmaniasis caused by Leishmania major.Multi-analytical platform metabolomic approach to study miltefosine mechanism of action and resistance in Leishmania.Immunization against full-length protein and peptides from the Lutzomyia longipalpis sand fly salivary component maxadilan protects against Leishmania major infection in a murine model.New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent Trypanosoma cruzi CL-14 Strain Are Highly Antigenic and Protective against Leishmania infantum Challenge.Antigenicity of Leishmania-Activated C-Kinase Antigen (LACK) in Human Peripheral Blood Mononuclear Cells, and Protective Effect of Prime-Boost Vaccination With pCI-neo-LACK Plus Attenuated LACK-Expressing Vaccinia Viruses in Hamsters.
P2860
Q26752532-D86E1E91-2BC5-4ABE-8C63-D8B90D019B9CQ26765026-6DC45E46-79F6-488B-82B3-A7DF83D25B9FQ28539173-7244C671-8F71-4087-A205-153B83E3C3B9Q28540810-C53B43B7-65B8-482A-B119-42CA3439182BQ28631811-3065BFD7-D3D0-4D79-8664-5B28048B5940Q28652690-53C26C26-CDC1-4FDE-A44F-4FCD80A2ECA5Q33583456-B076F206-A0FD-4E76-B071-750083148761Q33724960-9CEF5B73-FF83-4B07-8CBA-9F941CC9DBA9Q33796409-C27E4BC2-4CF4-4DEE-BBB9-1F3C54D5184BQ34087781-1AE847C5-1767-49CA-AF50-BF6427D7721FQ34667457-AB5A0CCA-A09E-4F95-9CC8-448A579C840FQ35517074-72340213-6AAC-4F89-9C1A-948D8A0CE8DFQ35532615-D26327AD-2CC2-425C-A98F-FAA106EE9FEFQ36327194-F2133752-2001-44E6-A82B-D8574F52C7D6Q36706960-05A684EE-8860-4163-B210-EBFB96EFBB28Q36758235-3E8D1572-3846-4DC0-9BFC-0E08B57F3C3EQ37597009-3E7D1466-9392-46C9-A0DB-A1F9BAFA0665Q38235456-66AB5F93-8B7A-4E3F-A76F-7989059EA614Q38643410-577371EF-0160-4AC4-83C4-4104B6F8C097Q40049613-18C4E69D-5080-415A-B227-510A12E8D69DQ40092006-5BF2C1EE-6EF0-4F0C-92AA-9A2FB4F2C6F3Q40196869-7801DAFA-EF00-4947-BBC7-AF72E60E9DADQ40513787-07F81C05-44C5-4A97-AFE2-D93D45DF4ED2Q40633289-EA8C3455-51ED-4A1E-8942-2E7BF3035B7AQ41059628-A886FD2F-7BF1-466B-B971-7F0D7DB6872BQ41628326-632436FB-D81F-4245-85A7-103991F397C7Q42321490-C5B65F08-B558-466A-8B6E-CCBF723F4877Q46070025-7E4EF8D2-3E5F-4083-A10B-5EF15A7ADB99Q46907074-AB1245D4-64AA-4FDA-A025-7200EBEAB615Q47094812-A6A4AD6A-6B1D-4276-A985-1CAB0382016DQ52723035-BAF5F8C1-9A28-4241-BFBC-E1E0876E9B27Q54217600-3ACB3BBD-2DD5-4D71-BED4-44E9C46EBDE2
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Case study for a vaccine against leishmaniasis.
@en
type
label
Case study for a vaccine against leishmaniasis.
@en
prefLabel
Case study for a vaccine against leishmaniasis.
@en
P2093
P1433
P1476
Case study for a vaccine against leishmaniasis.
@en
P2093
Ali Khamesipour
Jorge Alvar
Simon L Croft
P304
P356
10.1016/J.VACCINE.2012.11.080
P407
P478
31 Suppl 2
P577
2013-04-01T00:00:00Z